Literature DB >> 9000711

Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression.

G S Korbutt1, J F Elliott, R V Rajotte.   

Abstract

We prepared single-cell suspensions of Lewis rat ¿RT1(1/l)¿ testicular cells and cultured these in vitro for 48 h under conditions that promoted the formation of cellular aggregates. In the absence of systemic immunosuppression, the transplantation of a sufficient quantity of these aggregates (containing 11 x 10(6) cells, (75% Sertoli cells), together with 2,000 purified Lewis rat islets, reversed the diabetic state for >95 days in 100% (5/5) of the chemically diabetic Wistar-Furth ¿RT1(u/u)¿ recipients. Similar grafts consisting of islets alone or islets plus 50% fewer testicular cell aggregates survived for only 10 days. Functioning composite allografts harvested from normoglycemic animals at approximately 100 days showed healthy beta-cells in close association with Fas ligand-expressing Sertoli cells. Because no gene therapy protocol is required, the transplantation of composite grafts consisting of purified human allogeneic islets plus human allogeneic testicular cell aggregates can be applied in clinical islet transplantation as soon as it has been proven in a large animal model.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000711     DOI: 10.2337/diab.46.2.317

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  43 in total

Review 1.  New approaches to inducing the death of alloreactive lymphocytes.

Authors:  S M Krams
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Improved function of rat islets upon co-microencapsulation with Sertoli's cells in alginate/poly-L-ornithine.

Authors:  G Luca; R Calafiore; G Basta; M Ricci; M Calvitti; L Neri; C Nastruzzi; E Becchetti; S Capitani; P Brunetti; C Rossi
Journal:  AAPS PharmSciTech       Date:  2001-08-26       Impact factor: 3.246

Review 3.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

4.  Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Authors:  M W Bennett; J O'connell; G C O'sullivan; D Roche; C Brady; J Kelly; J K Collins; F Shanahan
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

5.  Beta-cell replacement.

Authors:  N M Desai; G S Korbutt; C F Barker; K J Lafferty
Journal:  Diabetologia       Date:  1997-10       Impact factor: 10.122

Review 6.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

7.  Nondividing, postpubertal rat sertoli cells resumed proliferation after transplantation.

Authors:  Payal Mital; Gurvinder Kaur; Barrett Bowlin; Nicky J Paniagua; Gregory S Korbutt; Jannette M Dufour
Journal:  Biol Reprod       Date:  2014-01-23       Impact factor: 4.285

8.  C-C Chemokine Receptor Type 2-Dependent Migration of Myeloid-Derived Suppressor Cells in Protection of Islet Transplants.

Authors:  Jie Qin; Yusuke Arakawa; Miwa Morita; John J Fung; Shiguang Qian; Lina Lu
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

Review 9.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

10.  Role of complement regulatory proteins in the survival of murine allo-transplanted Sertoli cells.

Authors:  Hak-Mo Lee; Byoung Chol Oh; Dong-Pyo Lim; Dong-Sup Lee; Jaejin Cho; Gene Lee; Jeong Ryul Lee
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.